Evidence map›Paper›PMID 10215749›Full record

Trial reportBritish journal of clinical pharmacology1999

Pharmacokinetics of intravenous and oral L-arginine in normal volunteers.

O Tangphao, M Grossmann, S Chalon, B B Hoffman, T F Blaschke

2 registry-linked trialsOpen access · bronzeAbstract readClinical TrialRandomized Controlled Trial
In one paragraph

Trial report in British journal of clinical pharmacology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02352740 nacompletednot on this mapstarted 2013, after this paper: background citation

Characterization of the Metabolic Fate of an Oral L-arginine Form in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.

TypeinterventionalSponsorInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'EnvironnementRan2013Enrolled32ConditionsOverweight, Hypertriglyceridemic WaistArmsA form Arginine, B form Arginine
NCT02354794 nacompletednot on this mapstarted 2014, after this paper: background citation

Effect of Oral Supplementation With One Form of L-arginine on Vascular Endothelial Function in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.

TypeinterventionalSponsorInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'EnvironnementRan2014 to 2014Enrolled36ConditionsOverweight, Hypertriglyceridemic WaistArmsOne form of arginine, placebo
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. The Emerging Role of Prediabetes and Its Management: Focus on L-Arginine and a Survey in Clinical Practice.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

O TangphaoDivision of Clinical Pharmacology, Stanford University Medical Center, California 94305-5130, USA.
M Grossmann
S Chalon
B B Hoffman
T F Blaschke
Geriatric Research Education and Clinical Center · USVA Palo Alto Health Care System · USStanford Medicine · US

Funding

XOLAIR IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH FOOD ALLERGYM01RR000070 · NCRR · STANFORD UNIVERSITY · PI RASGON, NATALIE L · 1985 to 2008
$32.4M
NCRR NIH HHS M01 RR000070NCRR NIH HHS RR-00070NIA NIH HHS AG-05627
6 · The paper itself

Abstract

aimsRecent studies in patients with cardiovascular diseases suggest potential for the use of orally administered L-arginine, the precursor of nitric oxide, as a therapeutic agent. This crossover study was designed to examine the pharmacokinetics of single i.v. and oral doses of L-arginine in healthy volunteers (n = 10).

methodsA preliminary control study (n = 12) was performed to assess the variation in plasma L-arginine concentrations when ingesting a normal diet. The observed variation was taken into account when interpreting the pharmacokinetic data obtained after exogenous administration.

resultsThe mean baseline plasma concentration of L-arginine in the control study was 15.1+/-2.6 microg ml(-1). After intravenous administration (30 g over 30 min), the plasma concentration reached 1390+/-596 microg ml(-1). The disappearance of l-arginine appeared biphasic, with an initial rapid disappearance due to concentration-dependent renal clearance followed by a slower fall in plasma concentrations due to nonrenal elimination. The peak concentration after oral administration (10 g) was 50.0+/-13.4 microg ml(-1), occurring 1 h after administration. Renal elimination was not observed after oral administration of this dose. The absolute bioavailability of a single oral 10 g dose of L-arginine is approximately 20%.

conclusionsThis study provides basic knowledge of L-arginine pharmacokinetics in healthy humans. Intravenous and oral administrations show at minimum a biphasic pattern. Further studies will assess whether a similar profile is observed when the drug is administered to patients.

Indexed as

Administration, OralAdultArea Under CurveArginineBiological AvailabilityCross-Over StudiesFemaleHumansInfusions, IntravenousMaleMetabolic Clearance RateMiddle AgedArginine

Identifiers

PMID10215749
PMCPMC2014227
OpenAlexW1586074051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.